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Abstract: We investigated and monitored in situ the wetting and dissolution properties of polymeric
nanofibers and determined the solid-state of a drug during dissolution. Piroxicam (PRX) was used
as a low-dose and poorly-soluble model drug, and hydroxypropyl methylcellulose (HPMC) and
polydextrose (PD) were used as carrier polymers for electrospinning (ES). The initial-stage dissolution
of the nanofibers was monitored in situ with three-dimensional white light microscopic interferometry
(SWLI) and high-resolution optical microscopy. The physical solid-state characterization of nanofibers
was performed with Raman spectroscopy, X-ray powder diffraction (XRPD), and scanning electron
microscopy (SEM). We showed that PRX recrystallizes in a microcrystalline form immediately after
wetting of nanofibers, which could lead to enhanced dissolution of drug. Initiation of crystal
formation was detected by SWLI, indicating: (1) that PRX was partially released from the nanofibers,
and (2) that the solid-state form of PRX changed from amorphous to crystalline. The amount,
shape, and size of the PRX crystals depended on the carrier polymer used in the nanofibers and
dissolution media (pH). In conclusion, the present nanofibers loaded with PRX exhibit a quasi-dynamic
dissolution via recrystallization. SWLI enables a rapid, non-contacting, and non-destructive method
for in situ monitoring the early-stage dissolution of nanofibers and regional mapping of crystalline
changes (re-crystallization) during wetting. Such analysis is crucial because the wetting and
dissolution of nanofibers can greatly influence the performance of nanofibrous drug delivery systems
in pharmaceutical and biomedical applications.
Keywords: wetting; in situ drug release; nanofibers; electrospinning; poorly water-soluble drug;
piroxicam; hydroxypropyl methyl cellulose; polydextrose; scanning white light interferometry
1. Introduction
In recent years, advanced polymeric nanofibrous drug delivery systems (DDSs) have been of
increasing use in pharmaceutical and biomedical applications. Such systems include oral dispersible
thin films, ophthalmic preparations, multifunctional wound dressings, and implanted DDSs [1–3].
These hybrid polymer nanofibers hold great promise with respect to drug therapy and tissue engineering
in both human and veterinary medicine. Nanofibers have a unique capability to modify material
properties, which could have a paramount effect on drug delivery performance. They possess
fiber structure dimensions at the nanoscale and a large outer surface-to-volume ratio, enabling
multiple alternatives in drug delivery. The conversion of polymer solutions to nanofibers by solution
electrospinning (ES) is affected by material, process, and ambient parameters [3–5]. The geometric and
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physicochemical properties of nanofibers depend, for example, on the nature of the solution, polymer
type, polymer chain conformation, viscosity, elasticity, and electrical conductivity, as well as on solvent
polarity and surface tension [4,5]. These structural fiber properties in turn can have a great impact
on the dissolution and drug release of fibers [6–11]. To date, however, our understanding on the
dissolution (drug release) behavior of polymeric nanofibers and related physicochemical mechanisms
is still limited. This is partially due to the fact that the nanofibers are challenging samples for analysis
due to their nanoscale size and brittleness.
In the state-of-the art literature there are many examples of how the geometric nanofiber properties
(size, size distribution, surface morphology, orientation) and porosity can greatly affect the dissolution
(drug release) and therapeutic efficiency of nanofibrous DDSs [6,12–14]. With poorly water-soluble
drugs, the limitations in drug release of the nanofibrous DDSs can delay the onset of drug action, cause
poor oral bioavailability, and ultimately decrease therapeutic effect. The geometric nanofiber properties
can be governed by the adjustment and control of the critical material, process, and environmental
parameters in an ES process [5,15,16]. Lately, increasing interest has been focused on developing ES
processes which could produce drug-loaded nanofibers of a specific quality and with reproducible
drug release. Due to the nanoscale size, controlling the quality and performance of such nanofibers is
still challenging. Consequently, the mechanisms of drug release associated with such novel polymeric
nanofibrous DDSs remain poorly understood.
Scanning white light microscopic interferometry (SWLI) is a high-depth resolution imaging
technique suitable for determining the geometric properties (i.e., fiber shape, diameter, and length),
porosity, and surface topography of nanofibrous DDSs [17]. Three-dimensional (3D) SWLI permits
rapid, non-contacting and non-destructive imaging of nanofibrous samples, since it requires neither
sample preparation nor modification. Recently, we applied SWLI and high-resolution scanning
electron microscopy (SEM) equipped with a customized measurement program for 3D surface
topography analysis of non-woven nanofibrous mats [17]. In pharmaceutical research, the use of
SWLI for investigating and non-contact imaging of the manufacturing processes and final products
is still limited. Sandler et al. and Genina et al. used SWLI to image 3D printed multi-layered
DDSs [18,19]. Hanhijärvi et al. applied SWLI to investigate the film surface properties of hydroxypropyl
methylcellulose (HPMC)-coated tablets [20], while O’Bryan et al. used it to image 3D printed microgels
intended for bioprinting applications [21]. Recently, Wickström et al. applied SWLI to characterize the
surface texture and surface roughness of antibiotic-loaded fiber-reinforced composite implants [22].
The aim of the present study was to provide insight into the wetting and early-stage dissolution of
drug loaded polymeric nanofibers. To gain an understanding of such phenomena, we monitored in situ
the wetting and drug release of fibers loaded with a poorly water-soluble drug (piroxicam, PRX), and
determined the solid-state of the drug during dissolution. Two hydrophilic polymers were investigated
in nanofibers: hydroxypropyl methylcellulose (HPMC) intended for the sustained drug release and
polydextrose (PD) intended for the immediate drug release of a poorly water-soluble drug [23,24]. We
combined SWLI and high-resolution optical microscopy to image PRX-loaded nanofibers in contact
with an aqueous medium, and the physical appearance and solid-state changes of nanofibers were
verified with scanning electron microscopy (SEM), Raman spectroscopy, and X-ray diffraction (XRD),
respectively. To our knowledge, this is the first time when such imaging and solid-state analyses are
applied in a complimentary fashion to investigate the dissolution of polymeric nanofibers.
2. Materials and Methods
2.1. Materials
Commercially available cellulose ether, hydroxypropyl methylcellulose, HPMC (Methocel K100M
premium CR, Colorcon Ltd., Dartford, Kent, UK), and polydextrose, PD (STA-LITE L90, 70% aqueous
solution of PD, Tate & Lyle Netherlands B.V., Koog Aan De Zaan, KA, Netherlands) (Figure 1) were used
as carrier polymers for the ES of nanofibers. The organic solvents were 1,1,1,3,3,3-hexa-fluoro-2-propanol
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(HFIP) (≥99.0%) (Sigma-Aldrich C.C., St. Louis, MO, USA) and methanol (Lach-Ner, s.r.o., Neratovice,
Czech Republic). Anhydrous piroxicam, (PRX, pure form I, PRXAH I, Letco Medical, Inc., N Livonia,
MI, USA) was selected as a model drug for a low-dose poorly water-soluble active substance in
nanofibers. In the wetting and dissolution experiments, purified water, hydrochloric acid buffer
solution, USP 28 (pH 1.2), and phosphate buffer solution (pH 7.2) were used as dissolution media. The
materials for the preparation of buffer solutions were of analytical grade and purchased from Lach-Ner,
s.r.o., Neratovice, Czech Republic.
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Fig re l formula of (A) hydroxypropyl methylce lulose (HPMC) and (B) polydextrose (PD).
2.2. Preparation of Fiber Mats
The carrier polymer (HPMC) and model drug (PRX) were first manually dry mixed with a mortar
and pestle at three different ratios (1:1, 1:2, and 1:4). Next, the pre-mixtures were dissolved in organic
solvent to obtain the 0.8% (w/V) solution of HPMC in HFIP as described in our previous study [16].
With PD, the aqueous solution of PD (70%) alone or the mixture of the aqueous solution of PD (70%)
and methanol (5:1) were used for ES. The amount of PRX in the 70% aqueous solution of PD (0.75 mL)
used for ES was 20 mg, and 0.75 mL contained 530 mg PD. The drug-loaded nanofibers were fabricated
with an in-house ES set-up equipped with a syringe system, automatic syringe pump, spinneret,
high-voltage power supply, and a grounded collector plate. The high-voltage power supply system
was a Gamma (Gamma High Voltage Research, Model ES3OP-10W/DAM, Ormond Beach, FL, USA).
For HPMC solutions, the ES distance and voltage between the spinneret and the collector plate were
8.0 cm and 7 kV, respectively. The pump rate of the automatic syringe pump (KdScientific, Model No:
KDS-250-CE, Geneq Inc, Montreal, Quebec, Canada) was 1.0 mL/h. For PD solutions, the ES distance,
voltage, and pump rate were 17 cm, 14 kV, and 2.0 mL/h, respectively. The prepared fibers were stored
in desiccators (above silica gel, with relative humidity (RH) of 0%) at ambient room temperature
(21 ± 2 ◦C) and in a refrigerator (6 ± 2 ◦C/RH 0%) prior to use.
2.3. Physical Appearance and Solid-State Characterization
The size and surface morphology of fibers were investigated with scanning electron microscopy,
SEM (Helios NanoLab 600, FEI Company, Hillsboro, OR, USA). The samples were coated with a 3-nm
gold layer in an argon atmosphere using a magnetron sputter prior to SEM imaging. Solid-state
characterization of the starting materials and the electrospun fibers were carried out with X-ray
diffraction, XRD (D8 Advance, Bruker AXS GmbH, Karlsruhe, Germany), and Raman spectroscopy
(B&W Tek Inc., Newark, DE, USA). In XRD, Cu Kα1 radiation (λ= 1.5418 Å, 40 kV, and 40 mA) was
used, and data were collected in the range of 5◦ and 35◦ 2θ with a step size of 0.2◦ 2θ. The brittleness
of the fibrous mats was detected by visual inspection and manual palpation with tweezers.
2.4. In Situ Wetting and Dissolution Tests of Fibers
For in-situ wetting tests, we applied the fiber mats as such and the tablets compressed from these
fibers. The initial-stage dissolution of the fiber mats were monitored by a high-resolution optical
Pharmaceutics 2019, 11, 491 4 of 12
microscopy (Microscope Leica DMLB equipped with the Leica Germany 5.0× and L50×/0.50 objectives
and Canon Power Shot 550 digital camera). A standardized drop (50 µL) of aqueous dissolution media
was gently placed in contact with a fiber mat at room temperature (21 ± 2 ◦C), and the dissolution was
monitored by taking micrographs at regular intervals.
Pieces of a fiber mat were manually compressed into small flat-faced tablets (discs) with a
miniaturized press (Specac Ltd., Orpington BR5 3FQ, UK) intended for preparing sample discs
for infrared (IR) spectroscopy analysis. The compression pressure was 196 MPa (2t/cm2) and the
compression time was 5 s. The tablets (discs) were 12.7 mm in diameter and 0.8–1.0 mm in thickness.
For in situ initial-stage dissolution experiments, one micro-pipette drop of purified water (2 µL) was
gently placed onto the surface of fibrous tablets at room temperature (21 ± 2 ◦C). The contact point of
the drop onto the tablet surface was kept as constant as possible.
The wetting and early-stage dissolution of fibrous tablets were monitored in situ with an in-house
3D scanning white light microscopic interferometry (SWLI). In SWLI, a light beam passes through an
interferometric objective (Nikon, Michelson type, magnification 120×) containing a beam splitter that
reflects half the incident beam onto a reference surface and passes the other half onto the test surface
(Figure 2). Light reflected from the test and reference surfaces recombines and interferes to form an
interferogram. The working principle and structure of SWLI is described elsewhere. For details see
Kassamakov et al. [25,26], Hanhijärvi et al. [20], and Paaver et al. [17]. In the present study, we obtained
three-dimensional (3D) images featuring 29 nm × 29 nm active pixel size from a 55 × 40 µm2 area. The
time period of 10 min prior to a subsequent drop was required for the complete SWLI analysis of
the tablets. Purified water (pH 5.6) and the USP 28 buffer solutions (hydrochloric acid buffer pH 1.2
and phosphate buffer solution pH 7.2) were used as dissolution media. The total number of optical
microscopy and SWLI images taken on the course of the in situ dissolution experiments was over 500
(including short video-clips). The number of samples was 3–6 in each analysis.
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The in vitro dissolution tests of the electrospun nanofiber mats and the pure PRX powder 
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Figure 2. Schematic diagram of scanning white light in erfe ometer (SWLI) and the experimental setup
for the in situ w tting and early-stage di solution of nan fibers.
A high-resolution scanni g electron microsco e (SEM) (Helios NanoLab 600, FEI Company,
Hillsboro, OR, USA) was used as a reference method to the S LI. A software-based measurement
function xT Microscope Control (FEI) was used to measure the horizontal dimensions of the nanofibers.
Samples were mounted on aluminum stubs with silver paint and were magnetron-sputter coated with
a 3-nm gold layer in an argon atmosphere prior to microscopy. ImageJ (vers. 1.50i) was used for fiber
size distribution analysis.
2.5. Dissolution Test
The in vitro dissolution tests of the electr spu nanofiber mat and the pure PRX powder samples
were perf rmed using an USP dissolution appar tus I (ba ket me hod) in a semi-automated dissolution
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system (Termostat-Sotax AT7, Sotax AG, Aesch, Switzerland). The concentration of PRX in the
dissolution medium was measured at 354 nm by using a UV-VIS spectrophotometer (Ultrospec III,
Biochrom Ltd, Cambourne, Cambridge, UK). The dissolution medium was 900 mL of purified water
(pH 5.6) and buffer solution (pH 1.2 or pH 7.2) maintained at 37 ± 0.5 ◦C as described in the USP 28.
The basket rotation speed was 50 rpm. The amount of PRX in the powder and nanofiber samples used
in the dissolution test was 20 mg. Six parallel tests were performed for each sample.
3. Results and Discussion
3.1. Physical Appearance of Nanofibers
The ES of PRX-loaded fibers with both HPMC and PD polymers resulted in yellowish and white
thin fiber mats with a porous internal structure, respectively (Figure 3). HPMC generated fibrous
mats with a nanoscale fiber diameter ranging from 100 nm to 400 nm and uniform fiber thickness
(Figure 3A,B,E). With PD, we found that due to the hygroscopic nature of PD, the ES of PRX-loaded
fibers was possible only in precisely controlled and optimized temperature and humidity conditions
(below 30 ◦C and 40% RH). The PD fiber mat consisted of individual short fibers reaching micron size
and a large spread in diameters (Figure 3C,D,F). The diameter of these fibers ranged from 400 nm to
5 µm, and the corresponding fiber mats were brittle (based on palpation with tweezers). A number of
spherical beads were observed (SEM) in the electrospun PD fiber mats (Figure 3C). This was due to the
high surface tension and low viscosity of the solution. The fiber mats prepared from the mixtures of an
aqueous PD solution and methanol, were smaller in diameter, more uniform in radial size, and less
brittle (based on visual inspection and palpation with tweezers). The thickness of an entire PD fiber
mat ranged from few microns to several tens microns (SWLI).
Pharmaceutics 2019, 11, x FOR PEER REVIEW 5 of 12 
 
in the dissolution medium was measured at 354 nm by using a UV-VIS spectrophotometer (Ultrospec 
III, Biochrom Ltd, Cambourne, Cambridge, UK). The dissolu ion medium was 900 mL of purifi d 
water (pH 5.6) and buffer solution ( H 1.2 or pH 7.2) maintained at 37 ± 0.5 °C as described in the 
USP 28. The basket rotation speed was 50 rpm. The amount of PRX in the powder and nanofiber 
samples used in the dissolution test was 20 mg. Six parallel tests were performed for each sample. 
3. Resu ts and Dis ussion 
3.1. Physical Appearance of Nanofibers 
The ES of PRX-loaded fibers with both HPMC and PD polymers resulted in yellowish and white 
thin fiber mats with a porous internal structure, respectively (Figure 3). HPMC generated fibrous 
mats with a nanoscale fiber diameter ranging from 100 nm to 400 nm and uniform fiber thickness 
(Figure 3A,B,E). With PD, we found that due to the hygroscopic nature of PD, the ES of PRX-loaded 
fibers was possible only in precisely controlled and optimized temperature and humidity conditions 
(below 30 °C and 40% RH). The PD fiber mat consisted of individual short fi ers re ching micron size 
and a large sp ad i  ameters (Figure 3C,D,F). The diameter of these fibers ranged from 400 m to 
5 µm, and the corresponding fiber mats were brittle (based on palpation with tweezers). A number 
of spherical beads were observed (SEM) in the electrospun PD fiber mats (Figure 3C). This was due 
to the high surface tension and low viscosity of the solution. The fiber mats prepared from the 
mixtures of an aqueous PD solution and methanol, were smaller in diameter, more uniform in radial 
size, and less brittle (based on visual inspection and palpation with tweezers). The thickness of an 
entire PD fiber mat ranged from few microns to several tens microns (SWLI). 
 
 
 
Figure 3. SEM images of piroxicam (PRX)-loaded hydroxypropyl methylcellulose (HPMC) (A,B) 
nanofibers and polydextrose (PD) (C,D) fibers. Magnification of SEM: 5000× (A), 10000× (B), 600× (C), 
and 5000× (D). (E) Fiber size distribution of the PRX-loaded HPMC nanofibers; (F) Fiber size 
distribution of the PRX-loaded PD fibers.  
Figure 3. SEM images of piroxicam (PR ed hydroxypropyl methy cellulose (HPMC) (A,B)
nanofibers and polydextrose (PD) ( , ) fibers. Magnification of SEM: 5000× (A), 10000× (B), 600×
(C), and 5000× (D). (E) Fiber size distribution of the PRX-loaded HPMC nanofibers; (F) Fiber size
distribution of the PRX-loaded PD fibers.
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3.2. Physical Solid-State Properties of Nanofibers
Recently, we reported that the electrospun HPMC nanofibers loaded with PRX are amorphous,
and they remain as an amorphous form during a short storage period [16]. In the present study,
we found that the ES of PD fibers loaded with PRX did not generate the corresponding amorphous
structure, or the produced PRX amorphous structure was very unstable and immediately recrystallized
as also discussed previously [27]. The solid-state properties of the electrospun PD fibers loaded with
PRX were investigated immediately after the preparation and after a 1-month short-term storage at 0%
RH and low temperature (6 ◦C). As seen in Figure 4 (I), the XRD patterns of electrospun fiber mats
showed an amorphous halo together with the characteristic crystalline reflections of PRX anhydrate
form I (PRXAH I) immediately after preparation. The XRD and Raman spectroscopy results (Figure 4
(II)) confirmed that PRX (PRXAH I) had lost some of its crystallinity during ES, but did not stay
amorphous. No other crystalline reflections (XRD) or spectral features (Raman) characteristic to the
known anhydrous PRX solid-state forms were observed in XRD diffractograms or Raman spectra.
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Key: (A) PRX anhydrate form I (PRXAH I); (B) Fibers immediately after preparation; (C) Fibers stored
for 30 days at 0% room humidity (RH) and low temperature (6 ◦C).
3.3. In Situ Wetting and Initial Dissolution of Fibers
Figures 5 and 6 show the high-resolution optical microscopy and SWLI results on the initial
stages of the release and issolution of PRX from the HPMC and PD fiber mats. Since PRX was
completely d ssolved in the HPMC solution, it is vident that the d ug is homogeneously dispersed
within nanofibers after ES, and hence the release would be uniform from fiber mats. Figure 5A
shows a time-lapse-like snapshot from a high-resolution optical microscope of what happens to
the PRX-loaded HPMC nanofiber mats during wetting and initial-stage dissolution. As shown in
Figure 5A, the polymeric HPMC-PRX nanofibers dissolved within 1–5 s in the aqueous dissolution
media used. According to the literature, PRX exists in an amorphous form in electrospun HPMC
nanofibers [16,17,28,29], and the amorphous state of PRX hastened the onset of wetting and premature
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drug release. In our study, in situ wetting and dissolution monitoring indicated that PRX recrystallizes
in a microcrystalline form immediately after wetting and release from the HPMC nanofibers. The PRX
microcrystals ranging from 0.2 µm to 12 µm in size were formed after the addition of a standardized
drop (50 µL) of purified water, hydrochloric acid (pH 1.2) or phosphate buffer (pH 7.2) solutions
onto the HPMC nanofiber mats (Figure 5A,C). The recrystallization of PRX was associated with the
formation of larger clusters of microcrystals.
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Figure 5. (A) Three phases identified in the release and crystallization of piroxicam (PRX) from
hydroxylpropyl methylcellulose (HPMC) nanofibers. High-resolution light microscopy image
(magnification 50×) validates the results obtained with SWLI (shown in Figure 6): I. PRX embedded in
the nanofibers. II. Crystallization inside or on the nanofibers. III. Recrystallization of PRX. The large
arrow indicates the propagation direction of the water front. Magnification 50×. (B) Representative
micrograph on the initial dissolution of PRX–loaded polydextrose (PD) fibers. Visible crystals of
PRX evident (high ighted with a black arrow) i side a red circle. Magnification 50×. (C) The PRX
crystals visible at 30 s after wetting of nanofibers (HPMC:PRX 1:4) by placing a small drop of different
dissolution media onto the surface of the fibrous sample: (C1) ydrochloric acid buffer solution pH 1.2;
(C2) purified water, p.w. (pH 5.6); (C3) phosphate buffer solution pH 7.2 (22 ± 2 ◦C). Magnification 50×.
The overall initial-stage dissolution behavior of freely water-soluble PD fibers loaded with PRX
was similar, but faster than that observed with the corresponding HPMC nanofibers. As seen in
Figure 5B, individual PRX crystals entrapped inside the PD fibers, and the release and dissolution of
PRX from the PD fibers progressed via crystal formation. The rapid dissolution of a carrier polymer
(PD) fostered the dissolution of PRX. The number and size of the PRX crystals differed from those
observed with HPMC nanofibers. With PD, the number of crystals detected was smaller and the
size of the crystals slightly larger (ranging from 0.3 µm to 15 µm) than with the HPMC n ofibers.
The PRX crystals were located (clu tered) inside the PD fibers (Figure 5B), which evidently could
advance the dissolution of PRX since PD is a freely water-soluble carrier material. Consequently, this
is an interesting approach to use freely water-soluble carrier polymer in electrospun fibers for the
improvement of drug dissolution rate. The dissolution behavior of both types of drug-loaded fibers
was verified with an established in vitro dissolution test (USP), and the results are shown in the next
section (Figures 7–9).
Figure 5C illustrates the status of the HPMC:PRX (1:4) nanofibers at 30 s after wetting the surface
of a thin nanofibers sample layer by a small rop (2 µL) of different dissolution media (hydrochloric
acid buffer s lution t pH 1.2, purified water, or phosphate buffer solution at pH 7.2). The number,
shape, and size of the PRX crystals depended on the pH of the dissolution media used. With all
dissolution media, the dissolution of nanofibers occurred via immediate crystal formation of PRX
(i.e., recrystallization to microcrystals). Rapid changes in the solubility of PRX were also observed
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with a high-resolution optical microscope. The largest PRX microcrystals and clusters (ranging from
few micrometers up to 10 µm) were present with phosphate buffer solution at pH 7.2 (Figure 5C3)
and the smallest (0.2–1 µm in size) with hydrochloric acid buffer solution at pH 1.2 (Figure 5C1). It
is evident that the recrystallization of PRX associated with the dissolution of HPMC nanofibers is
dependent on both the pH and viscosity of dissolution media (in the microenvironment of dissolving
nanofibers). Based on our findings, the lower pH of the dissolution media (pH 1.2) induces PRX to
recrystallize into small 0.2–1 µm microcrystals in the vicinity of dissolving HPMC nanofibers. In
addition, the subsequent formation of microcrystalline clusters occurred slower than that observed
with the corresponding nanofibers in the higher pH of dissolution media (pH 7.2). The release of drug
from nanofiber mat is shown to be also dependent on the mat thickness [30]. In the present study, the
thickness of the HPMC fiber mat was in the range of 2–3 µm (measured by SEM and SWLI).
The SWLI images on the surface of the tablets compressed from the drug-loaded HPMC nanofibers
are presented in Figure 6. Figure 6A shows a SWLI image of a tablet surface, where individual fibers
are visible: A(I) initial state of tablet (magnification 30×) and A(II) after wetting with 2 µL of water and
evaporating for 1 min. In the initial stage, the tablet surface is flat and there is no crystal formation
visible. This indicates that PRX is located in nanofibers and most likely is still amorphous. Point A(II)
is the first wetting point after adding 2 µL of water and evaporating for 1 min. Figure 6B illustrates
the surface of the same tablet after wetting with another 2 µL of water and evaporating for 10 min.
Initiation of crystal formation is visible indicating that PRX is partially released from the nanofibers (as
seen in Figure 6B). This indicates also that the solid-state form of PRX has changed from amorphous to
crystalline form. In contact with water, PRX anhydrate form I transfers to PRX monohydrate before
dissolving [27]. It is obvious that PRX monohydrate crystals are visible in SWLI images (Figure 6B,C).
Figure 6C shows that the surface of the same tablet after the identical wetting procedure applied to the
same spot for a third time. The release of PRX and crystallization occur rapidly, and most likely the
crystals of PRX monohydrate are instantly formed in the vicinity of nanofibers. This in turn leads to
the retarded quasi-dynamic dissolution of PRX. The present finding is in good agreement with our
previous study describing the dissolution behavior of PRX anhydrate and monohydrate forms [31].
In summary, the three phases of the initial-stage dissolution of PRX-loaded HPMC nanofibers
were observed with the present compressed tablets and with the corresponding free nanofiber mats
studied by SWLI and high-resolution optical microscopy, respectively. These phases are as follows (as
shown in Figures 5 and 6): (A) PRX is embedded in the nanofibers (in an amorphous state confirmed
by our earlier study [16]), and all nanofibers are intact prior to the water front moving into them; (B)
Crystallization of PRX starts inside the nanofibers; (C) Recrystallization of PRX is finalized after drug
release from nanofibers.
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Figure 6. Time-lapse of wetting induced piroxicam (PRX) crystallization on the fixed surface of the
tablet consisting of PRX-loaded hydroxypropyl methylcellulose (HPMC) nanofibers. The PRX release
is visualized by scanning white light interferometry (SWLI). Key: (A-I) Initial state of the tablet; (A-II)
After wetting with 2 µL of water and evaporating for 1 min; (B) After wetting a second time with 2 µL
of water and evaporating for 10 min; (C) After wetting a third time with 2 µL water and evaporating
for 10 min. The scale for height differences is changed according to changes in surface altitude (A—0
to 8 µm; C—0 to 90 µm). The diameter and thickness of tablet (disc) are 12.7 mm and 0.8–1.0 mm,
respectively. Magnification 30×.
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3.4. Dissolution of Fibers
Figures 7–9 show the early-phase dissolution curves for the PRX anhydrate form I (PRXAH I) in a
powder form, the PRX-loaded HPMC nanofibers, and PRX-loaded PD fibers. PRXAH I in a powder
form exhibited clearly a longer lag-time in the early-phase dissolution than that observed with the
drug-loaded HPMC or PD fiber mats. The early-phase dissolution of PRX anhydrous form I powder
was also dependent on the dissolution media used (the amount of PRX dissolved in purified water
within the first 15 min was only less than 3%). The present results are also supported by the results on
the dissolution behavior of PRX obtained in our previous study [31].
As shown in Figures 7 and 8, the HPMC nanofibers accelerated the immediate dissolution of PRX
compared to that obtained with pure PRX anhydrous form I in a powder form. With the drug-loaded
HPMC nanofibers, the early-phase dissolution of PRX was fast within the first 3 min followed by a
sustained-release phase (Figures 7 and 8). This accelerated dissolution is obviously due to an immediate
release of amorphous PRX from the surface of nanofibers and formation of PRX microcrystals in the
vicinity of nanofibers (as shown in Figure 5A). The initial drug release from the HPMC nanofibers
depended on the dissolution medium, and this finding was in line with the optical microscopy images
on the dissolution of HPMC nanofiber mats shown in Figure 5C. The subsequent sustained dissolution
phase of PRX observed with the HPMC nanofibers (Figures 7 and 8) is most likely partially due to the
gel formation of HPMC as the nanofibers are dissolved, thus forming a hydrophilic gel barrier for the
release of drug.
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Figure 8. Early-phase dissolution of piroxic m )-loaded hydroxypropyl methylcellulose (HPMC)
nanofibers freely set into the dissolution baskets (n 6). The ratio of a carrier polymer (HPMC) and
PRX is 1:4 in the nanofibers. Key: black curve—PRX anhydrate form I (PRXAH I) in a powder form;
red curve—HPMC: PRX nanofibers 1:4; ∆—purified water; #—pH 7.2; —pH 1.2. Standard deviation
(SD) in each time point is less than 0.5%.
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With the drug-loaded PD fibers, the initial-stage dissolution of PRX within the first 3 min was
somewhat slower than that obtained with the PRX-loaded HPMC nanofibers (Figure 9). This is
obviously due to the crystalline state PRX in the PD fibers, thus resulting in a short delay in the onset
of dissolution. In spite of a 3-min lag-time, over 70% of PRX was dissolved within 15 min in acidic
dissolution medium (pH 1.2) when formulated as PD fibers. The use of methanol as a co-solvent for ES
slightly improved the dissolution of PRX from the PD fibers compared to the corresponding fibers
electrospun with pure aqueous solution of PD (i.e., without any organic solvent component) (Figure 9).
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Figure 9. Early-phase dissolution of piroxicam (PRX)-loaded polydextrose (PD) fibers freely set into the
dissolution baskets (n = 6). Key: red curve—the fibers containing PRX anhydrate form I (PRX AH I) and
PD (electrospun from water solution); blue curve—the fibers containing PRXAH I and PD (electrospun
from a water-in-methanol 5:1 solution); ∆—purified water; #—pH 7.2; —pH 1.2. Standard deviation
(SD) in each time point is less than 1.4%.
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